[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-376633-105":59,"doc-detail-376633-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","shifting-the-cancer-screening-paradigm-blood-based-multi-cancer-early-detection-tests","Shifting the Cancer Screening Paradigm - Blood-Based Multi-Cancer Early Detection Tests","","Cancer remains a leading cause of death worldwide, driven in part by late detection that limits treatment effectiveness and availability. Many cancer types still lack validated screening approaches, resulting in drawbacks that lower patient compliance, increase unnecessary diagnostic workups, and raise overall healthcare costs. Multicancer early detection (MCED) tests offer minimally invasive alternatives by analyzing tumor-associated markers in body fluids and using artificial intelligence to detect multiple cancers and refine cancer-type identification.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/shifting-the-cancer-screening-paradigm-blood-based-multi-cancer-early-detection-tests/376633/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/shifting-the-cancer-screening-paradigm-blood-based-multi-cancer-early-detection-tests/376633.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is early cancer detection important?","Question",{"text":112,"@type":113},"Early detection helps avoid progression and metastasis, which improves the chance of effective treatment. Late detection often leads to fewer therapeutic options.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What challenges exist with current cancer screening programs?",{"text":117,"@type":113},"Many cancer types lack validated screening tests, and available methods can cause drawbacks such as overdiagnosis, false positives, radiation exposure, or invasiveness that reduces patient compliance.",{"name":119,"@type":110,"acceptedAnswer":120},"How do blood-based MCED tests aim to improve screening?",{"text":121,"@type":113},"MCED tests combine molecular analysis of tumor-related markers in body fluids with artificial intelligence to detect multiple cancers and help discriminate the underlying cancer type.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},376633,1790824158,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","cells  \nReview  \nShifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests  \nTiago Brito-Rocha 1,2, Vera Const¥ncio 1,3, Rui Henrique 1,4,5 and Carmen Jerânimo 1,5, *  \nCitation: Brito-Rocha, T.; Constâncio, V.; Henrique, R.; Jerónimo, C. Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests. Cells 2023, 12, 935. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cells12060935](10.3390/cells12060935)  \nAcademic Editor: Domenico Ribatti  \nReceived: 19 January 2023  \nRevised: 14 March 2023  \nAccepted: 15 March 2023  \nPublished: 18 March 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Cancer Biology and Epigenetics Group, Research Center (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC), Rua Dr. Antânio Bernardino de Almeida, 4200-072 Porto, Portugal  \n2 Master Program in Oncology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal  \n3 Doctoral Program in Biomedical Sciences, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal  \n4 Department of Pathology, Portuguese Oncology Institute of Porto (IPO-Porto), Rua Dr. Antânio Bernardino de Almeida, 4200-072 Porto, Portugal  \n5 Department of Pathology and Molecular Immunology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-513 Porto, Portugal  \n* Correspondence: [carmenjeronimo@ipoporto.min-saude.pt](carmenjeronimo@ipoporto.min-saude.pt); Tel.: +351-225-084-000 (ext. 7264); Fax: +351-225-084-199  \nAbstract: Cancer remains a leading cause of death worldwide, partly owing to late detection which entails limited and often ineffective therapeutic options. Most cancers lack validated screening procedures, and the ones available disclose several drawbacks, leading to low patient compliance and unnecessary workups, adding up the costs to healthcare systems. Hence, there is a great need for innovative, accurate, and minimally invasive tools for early cancer detection. In recent years, multicancer early detection (MCED) tests emerged as a promising screening tool, combining molecular analysis of tumor-related markers present in body fluids with artificial intelligence to simultaneously detect a variety of cancers and further discriminate the underlying cancer type. Herein, we aim to provide a highlight of the variety of strategies currently under development concerning MCED, as well as the major factors which are preventing clinical implementation. Although MCED tests depict great potential for clinical application, large-scale clinical validation studies are still lacking.  \nKeywords: cancer screening; multi-cancer early detection; MCED; liquid biopsy; biomarkers  \n1. Introduction  \nCancer represents a major public health concern, being the leading cause of death inmost countries. Indeed, 10 million deaths and 19 .3 million new cancer cases were estimated worldwide in 2020 [1] . This high mortality rate is mostly due to late detection, finding cancer when it has already progressed and metastasized, which significantly reduces effective treatment options. It is estimated that at least 15% of cancer-related deaths within 5 years could be avoided by early disease detection [2] . Hence, cancer screening and early detection should be prioritized, preventing cancer development by removing pre-cancerous lesions and avoiding its progression by","cbCaikIQxEJ0R8vZ","https://ap.wps.com/l/cbCaikIQxEJ0R8vZ","pdf",1385389,41,"English","# Introduction\n## Rationale for cancer screening and early detection\n## Limits of existing screening programs\n## Promise of multicancer early detection (MCED)","[{\"question\":\"Why is early cancer detection important?\",\"answer\":\"Early detection helps avoid progression and metastasis, which improves the chance of effective treatment. Late detection often leads to fewer therapeutic options.\"},{\"question\":\"What challenges exist with current cancer screening programs?\",\"answer\":\"Many cancer types lack validated screening tests, and available methods can cause drawbacks such as overdiagnosis, false positives, radiation exposure, or invasiveness that reduces patient compliance.\"},{\"question\":\"How do blood-based MCED tests aim to improve screening?\",\"answer\":\"MCED tests combine molecular analysis of tumor-related markers in body fluids with artificial intelligence to detect multiple cancers and help discriminate the underlying cancer type.\"}]","Shifting the Cancer Screening Paradigm - Blood-Based Multi-Cancer Early Detection Tests | PDF",1790220384,103]